Skip to main content
    D

    Day One Biopharmaceuticals Inc (DAWN)

    Official site

    BIOTECHNOLOGY

    $21.53
    +0.00 (+0.00%)

    Last updated: Apr 23, 2026 at 5:00 PM ET

    Day One Biopharmaceuticals Inc (DAWN) Financials: Revenue, Profit and Cash Flow

    Updated Feb 24, 2026. Financial statements from company filings, amounts in US dollars.

    Day One Biopharmaceuticals reported revenue of $158.18M for the fiscal year ended Dec 31, 2025, up 20.6% from the year before. That year, net income was -$107.32M with a net margin of -67.8%, operating cash flow was -$103.76M and free cash flow was -$104.08M. The quarter ended Dec 31, 2025 had revenue of $53.72M and net income of -$21.28M.

    Revenue and Margins

    The operating margin was -80.8% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$158.18M+20.6%89.1%-80.8%-67.8%
    Dec 2024$131.16MN/A96.0%-165.7%-72.8%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Dec 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$158.18M$131.16M$0$0$0$0$0
    Cost of revenue$17.21M$5.28M$383.00K$531.00K$199.00K$155.00KN/A
    Gross profit$140.97M$125.88M-$383.00K-$531.00K-$199.00K-$155.00KN/A
    Research and development$148.13M$227.70M$130.52M$85.62M$43.58M$9.10M$13.90M
    Operating income-$127.75M-$217.27M-$206.06M-$146.91M-$72.74M-$13.78M-$14.90M
    Net income-$107.32M-$95.50M-$188.92M-$132.18M-$70.44M-$40.51M-$12.63M
    EBITDA-$105.82M-$86.32M-$188.53M-$146.38M-$72.54MN/A-$2.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$53.72M$39.80M$33.91M$30.76M$29.21M$93.76M$8.19M$0$560.00K$0$0$0
    Gross profit$47.64M$35.31M$30.14M$27.88M$26.23M$92.17M$7.49M-$116.00K-$103.00K-$99.00K-$92.00K-$89.00K
    Operating income-$27.46M-$24.25M-$34.97M-$41.07M-$65.33M$29.64M-$114.81M-$66.77M-$59.52M-$51.44M-$49.25M-$45.85M
    Net income-$21.28M-$19.73M-$30.32M-$36.00M-$65.71M$37.04M-$4.41M-$62.41M-$54.51M-$46.15M-$45.86M-$42.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $174.00K by $196.90M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$507.83M$582.79M$376.05M$349.06M$289.82M$45.66M$27.34M
    Current assets$485.10M$562.33M$375.27M$347.87M$289.37M$45.07M$27.34M
    Cash and equivalents$197.08M$124.97M$230.78M$85.26M$284.31M$43.73M$27.33M
    Total liabilities$66.67M$80.04M$29.51M$17.02M$8.67M$2.20M$32.52M
    Short-term debt$174.00K$10.00K$408.00K$405.00K$204.00K$198.00KN/A
    Shareholder equity$441.16M$502.75M$346.54M$332.04M$281.15M$37.76M-$10.67M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$507.83M$513.78M$519.04M$534.36M$582.79M$600.81M$400.44M$326.64M$376.05M$414.18M$450.76M$323.56M
    Total liabilities$66.67M$62.91M$58.20M$54.84M$80.04M$45.34M$93.71M$29.84M$29.51M$24.55M$24.70M$23.15M
    Cash and equivalents$197.08M$43.28M$35.62M$33.36M$124.97M$422.76M$239.62M$270.39M$230.78M$241.18M$189.21M$49.27M
    Shareholder equity$441.16M$450.87M$460.83M$479.51M$502.75M$555.46M$306.73M$296.81M$346.54M$389.63M$426.05M$300.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$103.76M-$78.11M-$146.85M-$109.87M-$48.54M-$13.49M-$4.51M
    Capital expenditures$320.00K$2.17M$3.22M$26.00K$8.00M$92.00K$92.00K
    Free cash flow-$104.08M-$80.28M-$150.08M-$109.90M-$56.54M-$13.58M-$4.61M
    Investing cash flow$174.65M-$230.99M$128.38M-$255.07M-$8.00M-$92.00K-$92.00K
    Financing cash flow$1.22M$203.29M$164.00M$165.90M$297.12M$29.98M$30.91M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$14.15M-$5.80M-$24.81M-$59.00M-$30.01M$50.75M-$49.13M-$49.73M-$41.37M-$37.06M-$42.43M-$25.98M
    Capital expenditures$3.50M$3.82M$3.50M$3.82M$1.42M$55.72M$17.13M$0$8.00K$3.04M$149.00K$26.00K
    Free cash flow-$17.65M-$9.63M-$28.30M-$62.81M-$31.43M-$4.97M-$66.25M-$49.73M-$41.38M-$40.10M-$42.58M-$26.01M
    Last 12 quarters

    Frequently Asked Questions About DAWN

    What is Day One Biopharmaceuticals' annual revenue?

    Day One Biopharmaceuticals reported revenue of $158.18M for the fiscal year ended Dec 31, 2025.

    How fast is Day One Biopharmaceuticals' revenue growing?

    Revenue was up 20.6% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Day One Biopharmaceuticals profitable?

    No. Day One Biopharmaceuticals reported net income of -$107.32M for the fiscal year ended Dec 31, 2025, with a net margin of -67.8%.

    How much free cash flow does DAWN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$103.76M minus capital expenditures of $320.00K produced free cash flow of -$104.08M.

    How much debt does Day One Biopharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $174.00K and cash and equivalents of $197.08M.